DOSING OF ANTIDEPRESSANTS - THE UNKNOWN ART

被引:8
作者
JERLING, M
机构
[1] Dept. of Clinical Pharmacology, Huddinge Hospital
关键词
D O I
10.1097/00004714-199512000-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Data from a therapeutic drug monitoring service, in total 2,393 observations in 1,606 patients, were used to analyze factors associated with the prescribed daily doses of the tricyclic antidepressants amitriptyline and nortriptyline. The achieved concentrations in plasma were evaluated in relation to suggested therapeutic ranges. The doses of both drugs were greatly reduced with increasing age, despite the fact that age is of minor importance for their kinetics. Interactions with concomitantly given drugs were not handled by dose adjustments of the antidepressant. Therapeutic drug monitoring increased the proportion of concentrations within the therapeutic range for patients on amitriptyline, but not for those on nortriptyline. The large interindividual kinetic variability for most antidepressants requires individualized dosing, but this individualization is performed on incorrect grounds.
引用
收藏
页码:435 / 439
页数:5
相关论文
共 21 条
[1]   STEADY-STATE PLASMA LEVELS OF NORTRIPTYLINE INTWINS - INFLUENCE OF GENETIC FACTORS AND DRUG THERAPY [J].
ALEXANDERSON, B ;
EVANS, DAP ;
SJOQVIST, F .
BMJ-BRITISH MEDICAL JOURNAL, 1969, 4 (5686) :764-+
[2]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[3]   EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[4]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[5]   VALIDATION OF A THERAPEUTIC PLASMA-LEVEL RANGE IN AMITRIPTYLINE TREATMENT OF DEPRESSION [J].
BREYERPFAFF, U ;
GIEDKE, H ;
GAERTNER, HJ ;
NILL, K .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1989, 9 (02) :116-121
[6]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[7]   CONCOMITANT INTAKE OF NORTRIPTYLINE AND CARBAMAZEPINE [J].
BROSEN, K ;
KRAGHSORENSEN, P .
THERAPEUTIC DRUG MONITORING, 1993, 15 (03) :258-260
[8]  
BROWN CS, 1992, J CLIN PSYCHOPHARM, V12, P67
[9]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[10]   DRUG INTERACTION - INHIBITORY EFFECT OF NEUROLEPTICS ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN [J].
GRAM, LF ;
OVERO, KF .
BRITISH MEDICAL JOURNAL, 1972, 1 (5798) :463-&